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A.J. Saykin et al. / Alzheimer’s & Dementia 11 (2015) 792-814 793Results: ADNI genetic data have been downloaded thousands of times, and.300 publications have re-
sulted, including reports of large-scaleGWASby consortia towhichADNI contributed.Many of the first
applications of quantitative endophenotype association studies used ADNI data, including some of the
earliest GWAS and pathway-based studies of biospecimen and imaging biomarkers, as well as memory
and other clinical/cognitive variables. Other contributions include some of the first whole exome and
whole genome sequencing data sets and reports in healthy controls, mild cognitive impairment, and AD.
Discussion: Numerous genetic susceptibility and protective markers for AD and disease biomarkers
have been identified and replicated using ADNI data and have heavily implicated immune, mitochon-
drial, cell cycle/fate, and other biological processes. Early sequencing studies suggest that rare and
structural variants are likely to account for significant additional phenotypic variation. Longitudinal
analyses of transcriptomic, proteomic, metabolomic, and epigenomic changes will also further eluci-
date dynamic processes underlying preclinical and prodromal stages of disease. Integration of this
unique collection of multiomics data within a systems biology framework will help to separate truly
informative markers of early disease mechanisms and potential novel therapeutic targets from the vast
background of less relevant biological processes. Fortunately, a broad swath of the scientific commu-
nity has accepted this grand challenge.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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The Alzheimer’s Disease Neuroimaging Initiative
(ADNI) was initiated in 2003 by the National Institute on
Aging, the National Institute of Biomedical Imaging and
Bioengineering, the Food and Drug Administration (FDA),
private pharmaceutical companies, and nonprofit organiza-
tions as a public-private partnership. The first phase
(ADNI-1) launched a cohort study of patients with Alz-
heimer’s disease (AD), mild cognitive impairment (MCI),
and cognitively normal (CN) older adult controls. A second,
American Recovery and Reinvestment Act of 2009 spon-
sored, “Grand Opportunity” phase (ADNI-GO) followed,
and introduced the concept of early mild cognitive impair-
ment (EMCI). ADNI is now completing its third phase
(ADNI-2), which also assesses individuals with early or
late MCI (LMCI), mild AD, cognitively normal controls,
and a new group of older adults with significant memory
concerns (SMCs) but whose psychometric performance is
within normal limits [1], consistent with the recent
consensus concept of subjective cognitive decline [2].
Detailed information on ADNI is found on the study Web
site (http://www.adni-info.org/). The primary goal of
ADNI has been to establish the optimal panel of clinical as-
sessments, magnetic resonance imaging (MRI) and positron
emission tomography (PET) imaging measures, as well as
other biomarkers from blood and cerebrospinal fluid
(CSF), to inform clinical trial design for AD therapeutic
development. At the same time, ADNI has been highly pro-
ductive in generating a wealth of data useful for elucidating
disease mechanisms occurring during early stages of pre-
clinical and prodromal AD. For a comprehensive summaryof ADNI results, see the article by Weiner et al. [3] and
the other articles in this special issue.
Genetics has played an increasingly important role in AD
research over the past few decades, starting with the discov-
eries of rare mutations in APP (amyloid precursor protein),
PSEN1 (presenilin-1), and PSEN2 (presenilin-2) that cause
early-onset autosomal dominant forms of the disease (see
the study by Bateman et al. [4] for review) and continuing
with the association of the common APOE (apolipoprotein
E) ε4 allele with sporadic or late-onset AD (LOAD). Until
recently, only APOE on chromosome 19 had been robustly
replicated as a LOAD susceptibility gene. With the advent
of large-scale genome-wide association studies (GWAS)
conducted by multistudy consortia, a current “top 20” or
more list of replicated genes has emerged, which are now un-
dergoing further investigation to identify the biological basis
of their risk or protective roles in LOAD [5]. In ADNI,
APOE genotype was determined and DNA and cell lines
were banked from the beginning of the study. Genome-
wide genotyping was also completed, enabling ADNI data
to be included in several large and important GWAS studies.
Notably, most of these large well-powered meta-analytic
GWAS studies are restricted to binary categorical pheno-
types, such as clinical diagnosis, and usually only include
AD cases and controls.
A relatively unique aspect of ADNI is the systematic lon-
gitudinal collection of biomarker data that can serve as quan-
titative endophenotypes for genetic association studies. In
fact, using quantitative endophenotypes as target measures
has been found to improve power relative to case-control
techniques, as well as to avoid using arbitrary or potentially
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the value of these quantitative trait loci (QTL)
investigations in AD, the ADNI Genetics Core was
established at the beginning of the GO phase [8] with the
goals of: (1) blood sample processing, genotyping, and
dissemination; (2) genome-wide analysis of multidimen-
sional phenotypic data collected on the ADNI cohort; and
(3) serving as a central resource, point of contact, and plan-
ning group for genetic studies in ADNI. The first GWAS of
an ADNI quantitative phenotype was published in 2009 [9],
and progress has been rapid as groups worldwide analyzed
the publicly available ADNI genetic data. Shen et al. [10]
provided a detailed review of results from ADNI genetic
studies through 2012. Here, we provide an updated review
of these results through 2014, summarize the evolving set
of ADNI genetic data, and discuss future directions to maxi-
mally leverage these data that we hope will be incorporated
in the proposed next phase of ADNI.
The main goal of this update was to describe the genetic
data and highlight results generated to date as part of the
ADNI study. First, we describe the samples, methods, and
basic analysis of the different types of genetic data available
in ADNI, including APOE, TOMM40 (translocase of outer
mitochondrial membrane 40 homolog) poly-T repeat,
GWAS, whole exome sequences, whole genome sequences,
and microarray-based RNA gene expression profiles. This
documentation of techniques which have evolved over
time should assist the many users of ADNI genetic data to
better understand the processing pipelines. Second, we
discuss how and the extent to which the various ADNI ge-
netic data sets have been used so far. Third, we highlight
novel and important findings generated by relating quantita-
tive phenotypes to the ADNI genetic data. Fourth, we discuss
the findings from the ADNI data in the context of a systems
biology framework. Fifth, we describe how ADNI genetic
findings could inform drug development, as well as clinical
trial design and execution. This is followed by a discussion
of the potential for understanding disease biology using
induced pluripotent stem cells (iPSCs). Sixth, we describe
how ADNI and other genetic data relate to ethical, legal,
and social implications of genetic testing, for example, in re-
turning genetic results on disease risk. Finally, we discuss
future directions proposed by the Genetics Core that we
hope will be investigated in the proposed next phase of the
ADNI study.2. Materials and methods
2.1. Sample storage and processing2.1.1. Sample storage summary
Blood samples are collected at each visit for all partici-
pants (i.e., CN, SMC, EMCI, LMCI, and AD) according to
ADNI protocol for the particular study phase (http://www.
adni-info.org/Scientists/ADNIStudyProcedures.aspx). Allcollected samples are sent to and processed by the National
Institute on Aging–sponsored National Cell Repository for
Alzheimer’s Disease (NCRAD; http://ncrad.iu.edu/) accord-
ing to standard operating procedures briefly summarized
below (see Sections 2.1.2., 2.1.3, 2.1.4). Baseline blood
samples for ADNI-1 were received and processed by the
ADNI Biomarker Core with DNA extraction (described in
the following section) contributed by Pfizer and performed
by Cogenics (now Beckman Coulter Genomics). DNA was
then transferred to NCRAD. All samples of genomic mate-
rial are inventoried and tracked by NCRAD and the ADNI
Genetics Core. In addition, collection of PAXgene blood
RNA samples (three 2.5-mL tubes per participant) was initi-
ated in the ADNI-GO/2 phases. As of March 24, 2015, there
are 777 ADNI-1, 127 ADNI-GO, and 781 ADNI-2 partici-
pants with at least one DNA sample from genomic blood
stored at NCRAD. Eight hundred ten ADNI-1, 125 ADNI-
GO, and 772 ADNI-2 participants have at least one cell
line DNA sample. Because RNA collection was initiated
in ADNI-GO, only ADNI-1 participants who continued to
ADNI-GO/2 have RNA samples; 290 ADNI-1, 128 ADNI-
GO, and 780 ADNI-2 participants have at least one RNA
sample stored at NCRAD. Many ADNI-GO/2 participants
also have longitudinal RNA collection.
2.1.2. DNA extraction and processing
DNA is extracted from buffy coats using whole blood
collected in ethylenediaminetetraacetic acid (EDTA) tubes
or buffy coats preisolated at the site of collection. The salts
of the chelating agent EDTA are used as anticoagulants for
genetic testing as they preserve cellular components of
blood. Blood samples are centrifuged at 3000 rpm
(1500! g) for 10 minutes at room temperature, the plasma
is drawn off, and the buffy coat is removed. The buffy coat
contains nucleated cells containing DNA. DNA bound to
protein is separated using sodium dodecyl sulfate and pro-
teinase K. Then, alcohol is used to precipitate DNA from a
high concentration of sodium chloride. Precipitated DNA
is collected and transferred into 2- or 5-mL tubes after centri-
fugation and incubation. Once a homogeneous solution is
obtained and placed inside rotator, DNA concentration is
measured on a NanoDrop 1000 spectrophotometer and
DNA tubes are stored in the appropriate 280C freezer.
2.1.3. RNA extraction and processing
The Qiagen PAXgene Blood RNA Kit (Germantown,
MD,USA) is used to purify total RNA from 2.5mL of human
whole blood collected in a PAXgene Blood RNATube. The
procedure is performed using manual or automated proce-
dures. One 2.5-mL tube is processed to extract RNA and
the remaining tubes are stored at 280C. RNA extraction
is performed using the Qiagen QIAcube according to the
manufacturer’s protocol. One tube is stored in the 4C refrig-
erator before any sample preparation and centrifuged at
3000! g at room temperature followed by discarding super-
natant and mixing RNAse-free water or BR1 resuspension
A.J. Saykin et al. / Alzheimer’s & Dementia 11 (2015) 792-814 795buffer. Samples are then microcentrifuged using QIAcube,
and eluted samples are transferred to thermal screw cap tubes
for incubation for 5minutes using a benchtop oven preheated
to 65C. Quality and quantity of incubated RNA samples are
measured and RNA samples are aliquoted in 2-mL screw cap
tubes at 2 mg/aliquot and stored at 280C.
2.1.4. Lymphoblastoid cell lines
To establish lymphoblastoid cell lines (LCLs), whole
blood samples from the baseline visit are collected in two
8.5-mL tubes coated with acid citrate dextrose. LCLs are
created using the white blood cells from the buffy coat ex-
tracted from whole blood. Cell lines are immortalized by
transforming B lymphocytes with the Epstein-Barr virus.
White blood cells are placed in a flask along with a solution
that allows permanent cell growth and incubated at 37C for
between 4 weeks and 3 months. The cell-containing solution
is then divided and transferred into two larger flasks for
further cell growth. Cells are then placed in a vial, along
with a preservative, and gradually cooled to freezing temper-
ature to prevent damage to the cell line. The frozen cells are
stored in a liquid nitrogen tank at NCRAD.2.2. Genotyping and sequencing
2.2.1. APOE genotyping
APOE genotyping was done using DNA from blood sam-
ples from 818 ADNI-1, 128 ADNI-GO, and 778 ADNI-2
participants. For ADNI-1, APOE genotyping was carried
out by polymerase chain reaction (PCR) amplification,
Hhal restriction enzyme digestion, and subsequent standard
gel resolution and visualization processes [11,12]. For
ADNI-GO and ADNI-2 DNA samples, genotyping was per-
formed by Prevention Genetics (Marshfield, WI, USA) and
LGC Genomics (Beverly, MA, USA). Prevention Genetics
used array processing using allele-specific PCR with univer-
sal molecular beacons [13,14]. At LGC, assays were
performed using competitive allele-specific PCR, enabling
biallelic scoring of single nucleotide polymorphisms
(SNPs). Assay kits were added to DNA samples, followed
by thermal cycling reaction and an end-point fluorescent
read. Genotypes were called using LGC Genomics’
in-house Kraken software (http://www.lgcgroup.com/
products/genotyping-software/kraken/) and were returned to
the ADNI Genetics Core after manual quality control
(QC). All APOE genotype data underwent further QC
checks, including sex and identity checks, and potential
problems were identified and corrected through communica-
tion with NCRAD and other cores. Final quality-controlled
data were posted on the ADNI Laboratory of Neuro Imaging
(LONI) Web site (http://adni.loni.usc.edu).
2.2.2. TOMM40 poly-T repeat genotyping
The TOMM40 poly-T repeat was assessed in the ADNI-1
cohort because an association had been previously reported
between the TOMM40 poly-T repeat and AD [15]. Genotyp-ing was performed by Polymorphic DNATechnologies, Inc.
(Alameda, CA, USA) for 757 individuals from ADNI-1,
with support for the assays provided by Allen Roses (Duke
University). Details of the poly-T assay and bioinformatics
analyses using long-range PCR and DNA sequencing are
available in the study by Roses [15].
2.2.3. Genome-wide array genotyping
Genome-wide genotyping was performed using the Illu-
mina Human 610-Quad BeadChip (Illumina, Inc., San
Diego, CA, USA) for ADNI-1 individuals by TGen
(Phoenix, AZ, USA) and using the OmniExpress BeadChip
for ADNI-GO/2 individuals by the Center for Applied Geno-
mics of Children’s Hospital of Philadelphia (Philadelphia,
PA, USA). Detailed genotyping protocols were described
previously [8]. All assays were performed according to
manufacturer protocols. Bead intensity data were used to
call genotypes using BeadStudio 3.2 (Illumina) for the first
release of ADNI-1 data, GenomeStudio v2009.1 (Illumina)
for the second release of ADNI-1 data, and GenomeStudio
v2011.1 (Illumina) for ADNI-GO/2. All genotype data
were quality controlled, including checks for sex and iden-
tity, and the quality-controlled data were released on the
ADNI LONI Web site (http://adni.loni.usc.edu) in Final
Report and/or PLINK data formats. Of note, samples from
the 818 individuals in the whole genome sequencing
(WGS) substudy described below (Section 2.2.5) underwent
genome-wide genotyping using the Illumina Omni2.5M
BeadChip performed by Illumina. Thus, multiple genome-
wide genotype array data sets are available for some
ADNI participants. After QC, the Omni2.5M genotype
data in PLINK format were posted on the LONI Web site
(http://adni.loni.usc.edu) in February 2014.
2.2.4. Whole exome sequencing
Whole exome sequencing (WES) of 18 ADNI-1 partici-
pants with a diagnosis of MCI at baseline was performed
on blood-derived genomic DNA samples at TGen (www.
tgen.org/). Participants were selected for a small extreme-
trait design. Specifically, nine age- and education-matched
pairs of non-Hispanic Caucasian, male, right-handed partic-
ipants with amnestic MCI were selected on the basis of rapid
versus slowhippocampal volumechange onMRIover 2years
(nine participants with rapid rates of atrophy and nine with
slow rates of atrophy) [16,17]. All participants had APOE
ε3/ε3 genotype, as one goal of this small study was to
identify coding variants other than the APOE ε4 allele that
are associated with the rate of hippocampal volume loss.
Sequences were enriched through hybridization using the
Agilent’s SureSelect Human All Exon 50 Mb kit following
the manufacture’s protocol (www.genomics.agilent.com/).
The Agilent kit captured an exome that was approximately
50 Mb in size, covering w21,000 genes. These samples
could then be sequenced together on one lane of the flow
cell and segregated later for analysis using their molecular
bar codes as tags. Samples were sequenced across multiple
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libraries were sequenced on the Illumina HiSeq2000 using
paired-end read chemistry and read lengths of 105 bp. Each
sample was sequenced two times, and the resulting FASTQ
files were posted to the ADNI LONI Web site (http://adni.
loni.usc.edu) after QC.
2.2.5. Whole genome sequencing
Whole genome sequencing (WGS) was performed on
blood-derived genomic DNA samples from 818 ADNI-1/
GO/2 participants with support from the Brin-Wojcicki
Foundation and the Alzheimer’s Association. This research
sequencing was performed in a non-CLIA (see Section
4.4) laboratory at Illumina. Eight hundred ten of the ADNI
WGS data sets were released in August 2013. Samples
were sequenced on the Illumina HiSeq2000 using paired-
end read chemistry and read length of 100 bp at 30-40!
coverage. The resulting BAM and VCF files generated by Il-
lumina using the CASAVA software were archived at three
physical locations, including LONI at the University of
Southern California, Indiana University, and the Broad Insti-
tute. QC steps included participant sex check, participant
identity check, and variant quality check of the Illumina-
generated VCF files. The participant sex check was conduct-
ed by comparing sex estimated using Illumina Omni2.5M
GWAS data and self-reported sex information from the
ADNI database. Participant identity was cross-checked by
determining: (1) concordance of a subset of fingerprint
SNPs between prior genotype data and Omni2.5M genotype
data; and (2) concordance of all quality-controlled SNPs be-
tween Omni2.5M genotype data and WGS VCF data. The
quality of variants passing sequencing QC in the WGS
VCF files was assessed by comparing with Omni2.5M geno-
type data. Because Illumina’s CASAVA software calls vari-
ants on a single sample only, the Broad Institute converted
the BAM files into original FASTQ files, a text-based format
for storing both sequence reads and their corresponding
quality information in Phred format, and realigned and re-
called the variants using Broad GATK. Briefly, short-read se-
quences were mapped to the reference human genome using
BWA-mem, and potential PCR duplicates were removed.
After completing initial alignment, the alignment was
further refined by locally realigning any suspicious reads.
The reported base calling quality scores obtained from the
sequencer were recalibrated to account for covariates of
base errors such as sequencing technology and machine cy-
cle. Finally, the realigned reads were written to a BAM file
for further analysis. The analysis-ready BAM files were as-
sessed to identify all variants with statistical evidence for an
alternate allele present among samples using GATK Haplo-
typeCaller for multisample variant callings. Variants that
passed recommended variation quality criteria were assessed
by comparing with the Illumina Omni2.5M genotyping data
to estimate the concordance rate for each individual. Finally,
the resulting VCF files were posted to the ADNI LONI Web
site (http://adni.loni.usc.edu).2.3. Blood RNA expression microarray profiling
Gene expression or RNA profiling is a new type of data
for ADNI that has long been planned but was not previously
supported by existing funding. Fortunately, RNA profiling
on selected baseline blood samples was contributed by
Bristol-Myers Squibb (BMS) and performed at the BMS lab-
oratories for 811 ADNI participants included in the WGS
substudy. The Affymetrix Human Genome U219 Array (Af-
fymetrix, Santa Clara, CA, USA) was used for expression
profiling. Peripheral blood samples were collected using
PAXgene tubes for RNA analysis. Total RNAwas extracted
using the PAXgene Blood RNA Kit, following the protocol
provided by the manufacturer. The quantity and quality of
extracted RNA were assessed using the NanoDrop and the
Agilent Bioanalyzer, respectively. Blood RNA samples
from 64 participants did not pass QC and were excluded.
Samples were randomized to plates, with checks to ensure
sex and diagnosis balance, and hybridized to Affymetrix Hu-
man Genome U219 array plate. Array hybridization,
washing, staining, and scanning were carried out in an Affy-
metrix GeneTitan system. The quality of gene expression
data, including sample quality and hybridization and overall
signal quality, was analyzed using Affymetrix Expression
Console software and Partek Genomic Suite 6.6, according
to standard QC criteria provided by each software package.
Raw expression values obtained directly from CEL files
were preprocessed using the Robust Multi-chip Average
(RMA) normalization method [18]. The Affymetrix Human
Genome U219 Array contains 530,467 probes for 49,293
transcripts. All Affymetrix U219 probe sets were mapped
and annotated with reference to the human genome (hg19).
The Genetics Core performed several additional QC steps
using the RMA normalized expression array data. First,
the sex of samples was checked using sex-specific gene
expression data, including XIST and USP9Y [19]. Second,
sample identity was verified on the basis of expression
profiling to Omni2.5M genotype match using a Bayesian
method to predict individual SNP genotypes from gene
expression data [20]. Briefly, the 1000 most significant
SNP-transcript cis-eQTL pairs from quality-controlled
gene expression and genotype data were used to estimate
the posterior probability for a match between gene expres-
sion and genotype data. The quality-controlled gene expres-
sion profiles were completed and released to the ADNI
LONI Web site (http://adni.loni.usc.edu) in late April 2015.2.4. Metabolomic and lipidomic profiling
Another new and important data type for ADNI expected
to become available in mid-2015 is metabolomic profiling.
As a brief background, the metabolome is an organism’s
repertoire of metabolites or small molecules present in cells,
tissues, body fluids, and organ systems.Metabolomics is the
comprehensive study of metabolites and metabolism or
biochemical processes at the global or “-omics” level. In
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flects transcription processing and gene products, metabolic
profiling assays the end products of cellular processes and
can provide a more complete picture of cellular physiology
and pathophysiology. This is a relatively new and rapidly ex-
panding field that is recognized as having the potential to
significantly impact medical practice [21–24].
Over the past few years, the ADNI Biomarker and
Genetics Cores have collaborated with Dr. Rima Kaddurah-
Daouk (Duke University) and colleagues to initiate metabo-
lomic profiling ofADNI samples. Several initial studies were
conducted using samples from Duke and the University of
Pennsylvania [25–27]. Currently, ADNI-1 plasma samples
are being profiled, as are additional samples from the Indiana
University Memory and Aging Study (IMAS) [28]. Profiling
is expected to include broad biochemical coverage with
.500 metabolites measured in each participant to permit
analysis of metabolic changes within multiple pathways
and networks. A biochemical database will be created and
released on the ADNI LONI Web site (http://adni.loni.usc.
edu). We expect that baseline data from ADNI-1 will be pro-
filed and released by the end of 2015.3. Results
3.1. Data use statistics
Since the initial GWAS genotyping of ADNI-1 samples
by TGen, there were 31 sample requests fulfilled by
NCRAD. As of March 24, 2015, 8333 ADNI DNA samples
were used for APOE and GWAS genotyping, TOMM40
poly-T genotyping, WES, WGS, replication of genetic find-
ings from other cohorts, and other studies. Eight hundred
eleven RNA PaxGene tubes were used for the RNA expres-
sion profiling by BMS. ADNI genetic data dissemination is
managed and tracked by the Informatics Core based at
LONI. From 2009 through the end of 2014, ADNI GWAS
and/or other genetic data were downloaded approximately
107,000 times. For WGS, 12 sets of the extensive
(w150 TB) WGS raw data set (BAM files) have been
disseminated by hard drive array, which were return shipped
to requestors.
3.2. Publication statistics
Here, we briefly summarize the ADNI genetic studies
published up to January 1, 2015, where ADNI APOE,
GWAS, or sequencing data were used. We searched the
PubMed database using the EndNote X7 online search tool
with the following three criteria: (1) the “All Fields” contains
“Alzheimer’s Disease Neuroimaging Initiative”; (2) the “All
Fields” contains “APOE,” “apolipoprotein,” “gene,” “ge-
netic,” “genetics,” “genome,” “genomic,” or “genomics”;
and, (3) the “Year” field value is between 2008 and 2014.
We integrated the search results with the ADNI publication
database maintained by the ADNI Data and Publications
Committee. We manually reviewed all the abstracts andidentified 313 relevant ADNI genetic publications through
this extensive search. These publications include 2 in
2008, 9 in 2009, 38 in 2010, 36 in 2011, 60 in 2012, 69 in
2013, and 99 in 2014; see Supplementary Material
(ADNI_Genetics_papers_2008-2014.enlx) and Fig. 1A. In
these publications, ADNI genetic data were studied together
with one or more of the ADNI multidimensional phenotypic
data sets, including clinical information, structural MRI
(sMRI), advanced MRI such as diffusion tensor imaging
(DTI), resting-state functional MRI, or arterial spin labeled
perfusion MRI, [18F]florbetapir (AV-45/Amyvid) or [11C]
Pittsburgh Compound B (PiB) PET, [18F]fluorodeoxyglu-
cose (FDG) PET, CSF or plasma biomarkers, and/or cogni-
tive measures. Fig. 1 shows the distribution of ADNI genetic
publications grouped by assessed phenotype(s) from 2008 to
2014. Note that articles analyzing more than one phenotype
were counted multiple times in Fig. 1B. Fig. 2A shows the
word cloud of journal names where these articles were pub-
lished, where the color and size of a journal name correspond
to the number of articles published in that journal. Fig. 2B
and C show the word cloud of gene names appearing in
the article abstracts, where the color and size of a gene
name correspond to the number of abstracts mentioning
the gene. Note that Fig. 2B and C represent the results
with and without APOE included, respectively.3.3. Genetic association results by phenotype
Since the first ADNI GWAS publication by Potkin et al.
[9], numerous genetic analyses have used the ADNI data
alone or in combination with other cohorts. The articles pub-
lished between 2009 and 2012 were summarized in detail in
the studybyShen et al. [10]. Publications includingADNIge-
netic data continued to increase rapidly in 2013 and 2014. As
shown in Fig. 1, different types of qualitative and quantitative
phenotypes have been studied with genetic data in ADNI. In
the following sections, we summarize and selectively review
recent findings grouped by phenotypic category.
3.3.1. Clinical diagnosis (case vs. control)
One of the most prominent case-control studies in LOAD
was conducted by Lambert et al. [5], who performed a meta-
analysis of 74,046 individuals, including the ADNI cohort,
and identified 11 new susceptibility loci for LOAD. Boada
et al. [29] performed another multicohort study, including
ADNI, and identified a novel LOAD association at the aden-
osine triphosphate synthase, H1 transporting, mitochondrial
F0 (ATP5H)/potassium channel tetramerization domain–
containing protein 2 (KCTD2) locus. The ATP5H/KCTD2
locus has been related to mitochondrial energy production
and neuronal hyperpolarization during cellular stress condi-
tions. Leduc et al. [30] performed a three-cohort study,
including ADNI, and identified rs3846662 in the 3-
hydroxy-3-methylglutaryl-CoA reductase gene (HMGCR)
as a potent genetic modifier for AD risk, age of onset, and
MCI to AD conversion. This finding is noteworthy because
Fig. 1. ADNI genetic data usage and reports (2008–2014). (A) Total publications by year and (B) by phenotype category using ADNI genetic data are displayed.
“advMRI” indicates studies using advanced MRI techniques (diffusion tensor imaging, resting-state functional MRI, arterial spin labeling perfusion MRI);
“18F-Florbetapir or 11C-PiB” indicates studies using [18F]florbetapir or [11C]Pittsburgh Compound B (PiB); “18F-FDG” indicates [18F]fluorodeoxyglucose
(FDG) studies; “cognitive” indicates studies using neuropsychological test performance data; “clinical” indicates studies using clinical data, such as diagnosis;
“fluid biomarkers (CSF/plasma)” indicates studies using CSF or plasma-based fluid biomarkers; “sMRI” indicates structural MRI studies). Abbreviations: MRI,
magnetic resonance imaging; CSF, cerebrospinal fluid; sMRI, structural magnetic resonance imaging. *As of January 1, 2015; **Note that articles analyzing
more than one phenotype were counted multiple times in panel B.
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been demonstrated to reduce the risk of developing spo-
radic AD by as much as 70%, although no AD-related ben-
efits of statins have been shown in clinical AD patients.
Biffi et al. [31] performed a targeted genetic association
study in ADNI and identified variations in the oxidative
phosphorylation gene set associated with AD status and
conversion from CN to MCI. Kim et al. [32] performed
a gene-based analysis of relatively rare alleles (minor
allele frequency 0.03) in ADNI, coupled with several
other AD cohorts from database of Genotypes and Pheno-
types (dbGaP), and identified an association between
ZNF628 (zinc finger protein 628; a transcription factor
coding gene) and AD. Finally, Desikan et al. reported on
the genetic overlap between AD and Parkinson’s disease
(PD) based on large GWAS data sets including ADNI (to-
tal n 5 89,904) and identified a marker in the extended
MAPT (microtubule-associated protein tau) region (A
allele of rs393152) associated with both AD and PD
[33]. Comparisons of common and divergent pathways in
neurodegenerative diseases including AD, PD, amyotro-
phic lateral sclerosis, and other conditions appear to be a
promising strategy as discussed in the paper by Ramanan
and Saykin [34].3.3.2. Structural MRI
Data extracted from sMRI scans have been the most
widely analyzed phenotypes in ADNI genetic studies as
was described by Shen et al. [10]. As an example, Nho
et al. [16,17], using an extreme phenotype design discussed
above in Section 2.2.4, identified genetic variations within
PARP1 [poly(ADP-ribose) polymerase 1] andCARD10 (cas-
pase recruitment domain family, member 10) genes associ-
ated with a more rapid rate of hippocampal volume loss in
MCI. Recently, the same extreme phenotype imaging genetic
design was used to identify aREST (RE1-silencing transcrip-
tion factor) variant as protective [35,36], which was
consistent with an elegant independent series of analyses in
postmortem tissue and cellular models reported by Lu et al.
in Nature [37]. Hohman et al. [38,39] performed two ADNI
studies to examine genetic modification of the relationship
between other AD biomarkers and MRI-based neurodegen-
eration. In one study [38], they identified rs4728029 from
the POT1 (protection of telomeres 1) gene, which modifies
the relationship between tau phosphorylated at threonine
181 (pTau181) and ventricular dilation. In the other study
[39], they identified several SNPs that modify the relation-
ships between amyloid-b (Ab) or tau positivity and neurode-
generation. Roussotte et al. [40–43] performed a series of
Fig. 2. Common journals and reported genes in manuscripts using ADNI genetic data. (A) Aword cloud of journal names where articles using ADNI genetic
data were published is shown with the color and size of a journal name corresponding to the number of articles published in that journal. Word clouds of gene
names appearing in these article abstracts, (B) with and (C) without including APOE, are displayed with the color and size of a gene name corresponding to the
number of abstracts mentioning the gene.
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variant in the DAT1 [dopamine transporter; also known as
SLC6A3, solute carrier family 6 (neurotransmitter trans-
porter), member 3] gene associated with faster ventricular
expansion [40], combined effects of LOAD risk variants inthe CLU (clusterin) and APOE genes on ventricular expan-
sion [41], a common variant in the OPRD1 (opioid receptor,
delta 1) gene associated with smaller regional brain volumes
[42], and a variant in the RASGRF2 (Ras protein-specific
guanine nucleotide-releasing factor 2) gene associated with
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expansion [43]. Luis et al. [44] performed an MRI-based ge-
netic study on the TREM2 (triggering receptor expressed on
myeloid cells 2) AD risk variant (rs75932628), which
included ADNI and a Spanish cohort, and identified an asso-
ciation between the TREM2 variant and frontobasal gray
matter loss. Rajagopalan et al. [45] also found that carriers
of the risk-conferring variant in TREM2 had faster atrophy
in the temporal lobes than noncarriers. Koran et al. [46] eval-
uated the effect of genetic interactions within inositol-related
pathways on longitudinal MRI measures of the inferior
lateral ventricles and identified several genetic interactions
associatedwith longitudinal changes inventricle size.Andra-
wis et al. [47] demonstrated that APOE had a significant ef-
fect on longitudinal change in the hippocampus, with
greater change in MCI and AD participants who were
APOE ε4 positive. Finally, Apostolova et al. [48] demon-
strated that the APOE genotype alters the timing and sensi-
tivity of hippocampal volume and CSF biomarkers for
predicting MCI to AD conversion, with better prediction
using hippocampal volume inAPOE ε4–positiveMCI partic-
ipants and better prediction using p-tau inAPOE ε4–negative
participants.
3.3.3. Advanced MRI
ADNI-GO/2 introduced several advancedMRImodalities,
including DTI, resting-state functional MRI, and arterial spin
labeled perfusion MRI. In each case, these advanced tech-
niques were limited to sites using a particular scanner vendor,
effectively reducing the sample to about one-third of the
cohort for each scan type and limiting the power for genetic
analyses (see Jack et al. MRI Core report in this special issue).
Given the modest sample size of these data sets, only a few
genetic studies have been performed to date, using only the
ADNI DTI data. Notably, however, combining data from
two cohorts, Jahanshad et al. [49] performed the first
connectome-wide and genome-wide association study and
identified an association between a variant in SPON1 (spondin
1; rs2618516) and brain anatomic fiber connectivity. Warstadt
et al. [50] fitted a multilocus genetic model within white mat-
ter areas associated with serum cholesterol and identified that
CETP (cholesteryl ester transfer protein, plasma; increased
rs5882 G-allele dosage) was associated with higher fractional
anisotropy and lower radial and mean diffusivity on DTI.
Several publications also proposed new methods to boost
the power to detect genetic associations with diffusion imag-
ing measures in ADNI, by using bivariate genetic analysis of
MRI and DTI and an approach called “seemingly unrelated
regression” which integrates genetic information from
different imaging biomarkers [51–53].
3.3.4. Amyloid PET ([11C]Pittsburgh Compound B (PiB)
and [18F]florbetapir)
An early targeted study using a modest sized ADNI-1
[11C]PiB PET sample examined the amyloid pathway [54].
The number of genetic studies with amyloid PET pheno-types grew rapidly in 2013 and 2014. For example, Brad-
shaw et al. [55] examined the CD33 (CD33 molecule)
LOAD susceptibility locus (rs3865444) with the ADNI-1
[11C]PiB PET data and identified an association with
increased [11C]PiB binding. Ramanan et al. [56] performed
the first GWASwith amyloid PETas the phenotype using the
ADNI-GO/2 [18F]florbetapir scan data and reported that
APOE and BCHE (butyrylcholinesterase) were independent
modulators of cerebral amyloid deposition, together ac-
counting for nearly 15% of the variance in cross-sectional
amyloid burden. Thambisetty et al. [57] examined the CR1
[complement component (3b/4b) receptor 1] LOAD suscep-
tibility locus (rs3818361) using ADNI-1 [11C]PiB PET data,
combined with [11C]PiB PET data from substudies of the
Baltimore Longitudinal Study of Aging, and reported that
risk allele carriers had lower brain amyloid burden compared
with noncarriers. Swaminathan et al. [58] examined the as-
sociation between plasma Ab from peripheral blood and
cortical amyloid deposition on [11C]PiB PET and found
that this relationship was modulated by APOE ε4 genotype.
Murphy et al. [59] mapped the effects of APOE ε4 on ADNI
[18F]florbetapir scans and found a significant effect in the
four cortical regions examined. Risacher et al. [60] investi-
gated the role of APOE genotype in EMCI and found that
the APOE ε4 allele was associated with increased amyloid
accumulation on [18F]florbetapir PET, lower CSF Ab1–42
levels, and increased CSF tau levels in EMCI and CN.
Recently, Risacher et al. [1] also examined the role of
APOE in an expanded sample that included the new SMC
group introduced in ADNI-2. SMC participants who were
carriers of at least one APOE ε4 allele showed greater amy-
loid deposition on [18F]florbetapir PET, lower CSF Ab1–42
levels, and increased CSF tau levels compared with those
who were APOE ε4 noncarriers. Interestingly, an effect of
APOE ε4 was not observed for hypometabolism or medial
temporal lobe atrophy in the SMC group consistent with
the concept that those markers may be downstream of the
amyloid and tau proteinopathies detected by PET and in
CSF [61]. Finally, several amyloid PET studies examined
various facets of epistasis or gene-gene interactions. Yan
et al. [62] performed a transcriptome-guided amyloid imag-
ing genetic analysis and identified bimultivariate associa-
tions between APOE SNPs and brain-wide amyloid
imaging measures. Hohman et al. [63] examined epistatic re-
lationships between genes involved in amyloid and tau path-
ophysiology using [18F]florbetapir PET imaging as the target
phenotype. This study identified three significant interac-
tions between a SNP in GSK3b (glycogen synthase kinase
3 b; rs334543) and SNPs in each of the following genes:
APBB2 [amyloid b (A4) precursor protein-binding, family
B, member 2; rs2585590, rs3098914] and APP [amyloid b
(A4) precursor protein; rs457581].
3.3.5. [18F]fluorodeoxyglucose (FDG) PET
Relatively few recent reports specifically examined ge-
netic associations with [18F]FDG PET as an isolated
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analyses of genetics, [18F]FDG PET, and other imaging
and biomarker data for predicting outcomes of interest.
For example, Schraml et al. [64] proposed a hypometabolic
convergence index to provide a summarized measure of hy-
pometabolism on [18F]FDG PET and identified a significant
association between hypometabolic convergence index and
APOE ε4 dose using ADNI data. [18F]FDG PET measures
have also been analyzed with genetic data such as APOE
ε4 status, along with other multidimensional biomarkers,
to classify AD status [65], predict cognitive decline [66],
or predict MCI to AD conversion [67].
3.3.6. Fluid biomarkers (CSF and plasma)
Fluid biomarkers are another frequently analyzed cate-
gory of quantitative phenotypes used in ADNI genetic
studies. Kim et al. [28] examined the influence of genetic
variation on plasma protein levels using the multianalyte
Rules Based Medicine (RBM) panel and identified multiple
novel associations. For example, the CFHR1 (complement
factor H-related 1; rs7517126) and CFH (complement factor
H; rs6677604) genes were discovered to be very highly asso-
ciated with plasma complement factor H-related protein 1
(CFHR1) level. This study also confirmed previously identi-
fied gene-protein associations for the interleukin-6 receptor,
chemokine C-C motif (CC) ligand 4, angiotensin-converting
enzyme (ACE), and angiotensinogen. Cruchaga et al. [68]
performed a GWAS of CSF tau/pTau181 levels and identified
three loci: one between GEMC1 (geminin coiled-coil
domain containing; also known as GMNC) and OSTN (os-
teocrin), one within GLIS3 (GLIS family zinc finger 3),
and one within the TREM gene cluster. Chouraki et al. [69]
performed a genome-wide meta-analysis of plasma Ab pep-
tide levels and found a significant association between the
CTXN3 (cortexin 3) gene and plasma Ab1–42 levels. Kauwe
et al. [70] performed a GWAS of CSF levels of 59 AD candi-
date proteins and identified genetic associations with CSF
levels of five proteins, including ACE, chemokine CC
ligand 2, chemokine CC ligand 4, interleukin-6 receptor,
and matrix metalloproteinase-3. As mentioned earlier, Hoh-
man et al. performed two ADNI studies [38,39] to examine
genetic modification of relationship between CSF
biomarkers and MRI-based neurodegeneration and identi-
fied rs4728029 from the POT1 gene that modifies the rela-
tionship between pTau181 and ventricular dilation [38] and
several SNPs that modify the relationships between amyloid
or tau positivity and neurodegeneration [39]. Ramirez et al.
[71] performed a GWAS of CSF Ab1–42 and pTau181 levels
and found an association between Ab1–42 level and
rs62256378 in SUCLG2 (succinate-CoA ligase, GDP-
forming, b subunit), as well as an interaction between
APOE ε4 genotype and this SNP. In the aforementioned
study by Risacher et al. [1], individuals with SMC who
were APOE ε4 carriers showed lower Ab1–42 and higher
tau and pTau181 levels than SMC APOE ε4 noncarriers. A
recent cross-sectional and longitudinal analysis [72] of therelationship between CSF and PET amyloid biomarkers by
Toledo et al. [72] found that APOEmodified the relationship
between these AD biomarkers and suggested that they mea-
sure different aspects of Ab pathology in AD. Finally, as
mentioned previously, Apostolova et al. [48] found that
pTau181 was the best predictor for MCI to AD conversion
in APOE ε4–negative participants, whereas hippocampal
volume was the best predictor in APOE ε4–positive MCI
participants.
3.3.7. Cognitive performance
Studies including ADNI data have established that the ef-
fect of APOE on cognitive performance is more complex
than a simple extension of its association with AD risk
[60,73–76]. For example, one study demonstrated an
interactive effect of APOE and amyloid pathology on
cognitive decline, characterized by APOE ε4 carriers with
high amyloid burden exhibiting greater cognitive decline
[76]. This finding was consistent with an earlier analysis in
the Mayo Clinic Study of Aging that suggested that APOE
isoforms modify the association between amyloid load and
cognition [77].
Other genetic analyses of cognition have expanded the
scope beyond APOE to study other known AD risk loci
[74,78] and to discover novel associations. Sherva et al.
[79] reported that the SPON1 gene was associated with lon-
gitudinal global cognitive decline. This SPON1 finding is
notable in view of the aforementioned report of an associa-
tion of SPON1 with cerebral connectivity in both ADNI
and a young twin cohort [49]. Ramanan et al. identified an
association between the proapoptotic gene FASTKD2 (fas-
associated serine/threonine kinase domains 2) and cross-
sectional episodic memory performance [80,81]. The
memory GWAS by Ramanan et al. [80,81] is noteworthy
for its large sample consisting of data from the US Health
and Retirement Study (HRS), ADNI, AddNeuroMed, the
Religious Order Study, the Rush Memory and Aging
Project, and the IMAS yielding a total discovery and
replication sample of 14,781 individuals. The novel SNP
discovered in this study exhibited a protective effect on
memory performance and hippocampal structure (volume
and gray matter density on structural MRI) and was
associated with decreased CSF levels of apoptotic
mediators, consistent with a neuroprotective effect of this
gene variant. In related work, the ADNI data set
contributed to the large-scale genome-wide screens of brain
measures conducted by the Enhancing Neuro Imaging Ge-
netics through Meta-Analysis (ENIGMA) consortium [82].
In one analysis of GWAS data and MRI measures from
.50 cohorts worldwide, the ENIGMA consortium, in part-
nership with ADNI, discovered eight common genetic vari-
ants associated with the volume of subcortical brain
structures, including the hippocampus; several of the impli-
cated genes are associated in aggregate with disease risk and
have known roles in cell guidance, apoptosis, and other
physiological processes.
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covery of a primary association with a noncognitive pheno-
type, including ASTND2 (astrotactin 2) and GRIN2B
(glutamate receptor, ionotropic, N-methyl D-aspartate 2B)
with hippocampal and temporal lobe atrophy on MRI
[83,84], PSEN1 (presenilin-1) with CSF amyloid levels
[85], and DAT1 with AD case-control status [40]. Alterna-
tively, pathway analysis has been used to elucidate collective
effects of multiple genes on memory [86], executive func-
tioning [87], and depressive symptoms [88]. Notably,
pathway analysis of memory in the ADNI-1 sample
(N 5 742) [86] displayed substantial overlap of underlying
mechanisms (particularly of pathways related to cholinergic
neurotransmission, cell adhesion, and inflammation) with a
subsequent pathway analysis of memory in the population-
based HRS sample (N5 6705) [80], highlighting the poten-
tial utility of pathway-based approaches [34,89] to yield
replicable associations from otherwise diverse studies.
Overall, these findings provide a foundation for meeting
the broader ADNI aim of enhancing clinical trial design
and interpretation. Cognitive phenotypes are thought to
have substantial heritability (up to 80%) based on twin
studies, but a substantial portion of this heritability is still un-
characterized, and known genes appear to exhibit modest in-
dividual effect sizes [90–92]. Although APOE has shown the
most consistent relationship with cognition in AD and non-
AD settings, its effects depend on interactions with other
factors such as age [73,93,94] and biomarker status
[60,75], so accounting for these interactions might
facilitate risk enrichment and stratification in clinical trials
[95]. The use of genetic profiling for risk stratification to
enhance clinical trial design is discussed in greater detail
in Section 4.2. Other heavily investigated genes, such as
BDNF (brain-derived neurotrophic factor) [96–98] and
KIBRA (WWC1; WW and C2 domain containing 1)
[99–102], have displayed inconsistent relationships with
cognitive outcomes, potentially due to the complexity of
the cognitive “phenome” where individual cognitive
domains may have distinct genetic and molecular
architectures. Furthermore, cognitive tasks vary in their
domain specificity and domain overlap [90,91]. Integrative
analytic methods, as discussed in Section 4.1, may be useful
for untangling this complex phenotypic architecture [103].
In addition, low-frequency, rare, and copy number variants
may now be readily analyzed using the recently available
ADNI WGS data allowing assessment of contributions of
these features in cognitive performance.
3.3.8. Multidimensional data mining
Besides examining genetic effects of different ADNI phe-
notypes, some studies have integrated ADNI genetic data
with multidimensional phenotypic data sets to jointly predict
outcomes of interest. For example, Trzepacz et al. [104]
compared the power of three neuroimaging modalities
(sMRI, [11C]PiB PET, and [18F]FDG PET), coupled with
APOE genotype, for predicting MCI conversion to AD.Zhang et al. [105] compared several feature selection and
machine learning algorithms, where ADNI multidimen-
sional data sets, including genetic data along with sMRI,
[18F]FDG PET, and CSF biomarkers, were used to classify
CN, MCI, and AD participants. As mentioned previously,
multimodal ADNI data sets including APOE ε4 status,
CSF biomarkers, MRI, and [18F]FDG PET have been used
as predictors to classify AD status [65], predict cognitive
decline [66], or predict MCI to AD conversion [67].4. Discussion
Overall, the many reports evaluating ADNI genetic data
using multidimensional phenotypes from rich ADNI data
sets confirmed key findings in the genetics of AD and also
identified novel candidate genes that deserve further investi-
gation and replication in independent cohorts. In the
following sections, we discuss several key themes related
to the significance and implications of genetic studies using
ADNI data and plans for the ADNI Genetics Core going
forward.4.1. Toward a systems biology of AD: integrating
multiomics data at the pathway and network level
LOAD is thought to have a complex etiology, with multi-
ple genetic and environmental factors presumed to influence
susceptibility [106]. This complex model of susceptibility
can pose conceptual challenges to the “one-gene/one-
enzyme/one-function” paradigm that has been used to char-
acterize disorders with more simple genetic architectures
[107,108]. In response to such challenges, systems biology
approaches have been developed that attempt to model
complex and interactive multilevel biological systems
using a range of advanced computational and experimental
tools. These approaches are based on the hypothesis that
complex genetic architectures can only be appropriately
characterized through analytic strategies designed to
capture this complexity [109–111]. In practice, these
approaches rely on two fundamental premises, namely that
(1) genes and their variants are not isolated inciting
entities but rather exist within broader functional pathways
and networks [89] and that (2) diseases and their endopheno-
types are not isolated end points but rather are collections of
perturbations at multiple biological levels, including the
genome, epigenome, transcriptome, proteome, and metabo-
lome [103,112]. Fig. 3 illustrates the landscape of multiple
“-omics” domains relevant to AD. It is striking that ADNI
has collected data spanning a broad range of these domains
(indicated by asterisks in the figure).
One systems biology approach that has been applied to
AD starts with an initial discovery of a gene in one “-omics”
realm and progresses to test the effect of this gene in comple-
mentary biological systems. This strategy can be particularly
effective in characterizing the downstream consequences of
a genetic variant to fill in knowledge gaps native to most
Fig. 3. Converging “multi-omics” in ADNI. This figure illustrates the landscape of multiple “-omics” domains relevant to AD. Note that ADNI has collected
data spanning a broad range of these domains (indicated by asterisks; * 5 data from ADNI-1, ** 5 data from ADNI-GO/2). Image sources include upload.
wikimedia.org (indicated by y) and www.uphs.upenn.edu (indicated by z).
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proof-of-concept examples of this approach that have used
ADNI data, and it seems likely that this approach could be
productively extended to other AD-related genes. One inte-
grative functional genomics report followed up on the
immune system gene CD33, which was previously impli-
cated in AD through GWAS [113,114], by demonstrating
SNP-associated changes in CD33 expression (protein),
phagocytic performance of CD33-expressing monocytes
(cellular function), and amyloid accumulation measured
by PET imaging (brain pathology) [55]. It is notable that
CD33 is expressed selectively in microglia in AD brain tis-
sue [115], is a modulator of microglial activation, and also
constitutes a druggable target that has been investigated in
acute myeloid leukemia and very recently in AD [116].
Another example, discussed in Section 3.3.7, used GWAS
to discover a novel association of the proapoptotic gene
FASTKD2 with better episodic memory performance and
subsequently related the memory-associated SNP to lower
FASTKD2 mRNA expression (transcript), lower CSF levels
of fas-mediated apoptotic factors (protein), and higher hip-
pocampal volume and gray matter density (brain structure)
[80]. Like CD33, FASTKD2 also shows promise as a drug-
gable target based on earlier work in oncology [81]. Future
extensions of this systems biology strategy might addition-
ally leverage the ADNI WGS data, as AD-associated genes
are likely to contain rare variants with functional implica-tions in addition to the common variants detected by
GWAS [117].
Alternatively, systems biology approaches can start with
larger gene sets (pathways or networks) identified through
“-omics” analysis and subsequently use the known biolog-
ical relationships within those groups to converge on one or
more gene targets. Two recent examples of this approach,
including one using ADNI data [118], identified novel reg-
ulatory gene targets through network analysis of postmor-
tem brain tissue transcriptome data. In one report, a
network enriched with immune system and microglia-
related genes that is upregulated in postmortem AD brain
tissue was found to contain TYROBP (TYRO tyrosine
kinase–binding protein) as a common regulator of many
of the genes in the network [119]. Another report identified
networks with perturbed gene expression in AD and APOE
ε4 carriers and discovered RNF219 (ring finger protein
219) as a key mediator of these transcriptomic changes
[118]. Variants in RNF219 were additionally found to be
related to increased amyloid deposition by in vivo PET im-
aging [118]. Overall, the network strategy is particularly
attractive for its ability to highlight broad ensembles of
genes serving as effectors that drive key disease mecha-
nisms and, thus, may hold strong potential for identification
of promising therapeutic targets [120].
With rich phenotype and genotype data now available for
participants spanning the continuum from normal aging to
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(Section 4.5) will provide an ideal setting for systems
biology approaches to elucidate missing pieces in the under-
standing of AD pathophysiology and to potentially expand
the scope of AD diagnostic and therapeutic strategies.
From a risk prediction standpoint, networks exhibiting coex-
istent genetic variation and biological perturbation would
represent prime targets in the development of personalized,
burden-based genetic susceptibility tests [121]. For thera-
peutic development, pathways and networks displaying mul-
tiomics relationships with ADwould reduce the search space
for rational drug design and may highlight “hub” genes for
therapeutic cocktail approaches, such as in the polyphar-
macy strategies successfully used for AIDS and various can-
cers [34,112].4.2. Implications for clinical trial design and precision
medicine
4.2.1. Use of genetics in clinical trial design
The prospect of a personalized or precision medicine for
AD, and for its incorporation in therapeutic trial design, is
predicated on the ability to use an individual’s genetic pro-
file to refine predisposition to disease, characteristics such
as likely rate of progression, and predicted therapeutic and
side effect responses to various therapeutic strategies. At
present, the utility of genetic data with regards to AD clin-
ical drug development has been largely limited to APOE.
Unfortunately, the past decade of clinical drug develop-
ment programs for AD-modifying therapies has been
burdened with failures. Although these failures may be a
result of lack of drug efficacy, the inability to measure
drug response in homogenous patient populations has
contributed an unquestionable source of variability in these
programs. APOE’s strong and well-replicated associations
with multiple clinical and functional disease end points
and quantitative traits such as brain volume, age at disease
onset, amyloid deposition, and disease risk provide suffi-
cient effect size and predictive value to serve utility in clin-
ical development programs [5,56,122,123]. APOE is
commonly used in clinical trial analyses as a stratifying
factor or covariate to adjust for heterogeneity, although
independently it has failed to show consistent therapeutic
effect on drug response within this context [124,125].
However, APOE did predict dose-related side effects (vaso-
genic edema and stroke). APOE is also being used to select
patients for two large drug trials targeting at-risk but CN
individuals, the Alzheimer’s Prevention Initiative APOE
and TOMMORROW trials, where this genotype provides
an inexpensive and minimally invasive biomarker to iden-
tify individuals with high risk of AD. Both APOE and the
adjacent TOMM40 gene are being used for patient selection
in the TOMMORROW trial. The small effect sizes of the
other .20 confirmed markers from large GWAS studies
have to date limited their utility for trial design and strati-
fication. Polygenic scoring and related risk aggregationstrategies may prove useful in addressing the cumulative
contributions of multiple genes and pathways [126,127].
Similarly, analysis of gene-gene and gene-environment in-
teractions, while increasing complexity, is likely to provide
important insights relevant for trial design and analysis. As
additional information becomes available from multiple
sources, the combinatorial roles of genes in targeted path-
ways are expected to become increasing important for trial
design.
4.2.2. Use of genetics in therapeutic target identification
Sources of human variability (genotypic and phenotypic)
continue to be characterized in extraordinary detail, scale,
and speed, presenting unprecedented opportunities for dis-
covery and development of novel and targeted therapeutic
hypotheses. This requires robust insights into relevant hu-
man biology. Fig. 4 provides an overview of the path from
genetic signal detection to targeted therapeutics, including
methods and tolls, as well as implications for trial design,
as discussed previously. The value of genetic and related
data in medicine development has been exemplified by a
new paradigm for novel and targeted drug discovery in
oncology [128,129]. Three critical tipping points appear to
have now been reached for the key principles of this
paradigm to be extended to drug discovery and
development in neurodegeneration: (1) unprecedented
technologies to characterize genotypic and phenotypic
causes and consequences of human disease variability; (2)
dense genotype-phenotype data being generated by large-
scale public and private sector investments; and, (3) transla-
tional systems available to derive novel insights into disease
biology and pharmacology from genetic signals. Consider-
able effort is being invested to leverage and translate human
genetic and related data into opportunities for target discov-
ery and validation, understanding disease biology, and pa-
tient stratification and enrichment.
Retrospective analyses of drug discovery pipelines indi-
cate that novel therapeutic hypotheses supported by robust
human genetic data have a greater likelihood of success-
fully delivering new, impactful medicines [130]. Strategi-
cally, premising drug discovery pipelines on a foundation
of robust human data provides an opportunity for smaller,
focused research portfolios of higher confidence targets
(contrasting with historical “shots on goal” strategies of
pursuing a large number of lower confidence targets with
a high rate of attrition [131]). Moreover, advances in ap-
proaches to integrate genetic, intermediate trait, and clin-
ical outcome data provide opportunities to distinguish
causal relationships from correlative associations based
on the principles of Mendelian randomization [132].
Within the drug discovery industry, two applications of
such integrated data are to identify opportunities for target
discovery (forward genetics: where a new therapeutic hy-
pothesis is developed subsequent to identification of robust
genetic signal) and target qualification (reverse genetics:
where human genetic data are used to “validate” a
Fig. 4. Path from genetic signals to targeted therapeutics: key applications to drug discovery and development. This figure shows an overview of the path from
genetic signal detection to targeted therapeutics and implications for trial design. Abbreviations: eQTL, expression quantitative trait loci; pQTL, proteomic
quantitative trait loci; mQTL, metabolic quantitative trait loci; iPSC, induced pluripotent stem cells.
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preclinical animal models).
The growing list of genes identified as being robustly
associated with AD has recently identified several potential
novel therapeutic targets and target pathways. ADNI data
have contributed significantly to such findings. For
example, recent genetic association findings highlight auto-
immune and inflammation-related mechanisms as being
potentially causal in AD [133]. Autoimmune mechanisms
may provide opportunities for novel therapeutic targets
for the treatment or prevention of AD, especially as such
mechanisms may provide additional therapeutic value
beyond established target pathways such as Ab and tau
[134]. Specific examples of immune-related genes associ-
ated with AD risk and/or related intermediate traits include
TREM2 and CD33 [55,135]. The dense genetic,
multimodal phenotypic, and clinical data (including in a
longitudinal setting) in ADNI have contributed to better
understanding of associations of these genes with AD,
including the potential pathways and mechanisms
involved [55]. As the number of genes and pathways iden-
tified as being associated with neurodegenerative diseases
grows [34], ADNI provides an important resource to better
understand such associations and help contribute to the
translation of such associations into therapeutic hypothe-
ses. This contribution may be enhanced given the potential
to incorporate functional genomic and mechanistic data in
the future.
4.2.3. Use of genetics in novel biomarker identification
Genetic studies are instrumental in elucidating the path-
ways involved in the etiology of AD and in discovering
and validating drug targets. A parallel approach can also
be used to identify disease biomarkers. Identification of
the TREM2 rare variant and its association with AD risk
has sparked renewed interest in the field in understandingthe role of inflammation [135]. As this mutation is rela-
tively rare, it likely has little clinical utility as a biomarker
of disease heterogeneity. However, in part because of this
and other immune-related genetic findings, there is
renewed appreciation of the need for finding blood bio-
markers or imaging methods that track neuroinflammation.
Pathway analysis approaches can be used to identify such
biomarker targets, as was demonstrated by Zhang et al.
[119]. As our understanding of disease complexity in AD
matures, genomic science can help to elucidate underlying
biology, bringing together multiple levels of “-omics” data
to the level of individual variability to uncover novel sig-
nals and biomarkers that may segregate with disease
subtypes.4.3. Understanding AD biology through iPSCs
Cancer research has benefited from renewable sources of
cell lines derived from tumors carrying alterations of major
oncogenic pathways to enable drug screening and character-
ization. By contrast, drug discovery in neurodegenerative
diseases such as AD has mostly relied on animal models.
Advances in iPSC technology have opened new opportu-
nities for creation of novel human-derived in vitro models
to help bridge the gap between animal models and clinical
development.
iPSCs can be generated from various adult cell types
such as skin fibroblasts, hair follicle keratinocyte, or liver
or blood cells. Similar to embryonic stem cells, iPSCs
can self-renew and be differentiated into all three germ
layers to allow further investigations in relevant tissue/
cell types [136]. The first iPSCs for AD were generated
from fibroblasts of familial AD patients carrying mutations
in PSEN1 or PSEN2 [137]. Neurons differentiated from
these iPSCs have elevated Ab1–42 secretion, which can be
modulated by gamma-secretase inhibitors. A later study
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familial AD, sporadic AD, and nondemented controls.
Similar to the earlier report, differentiated neurons from
iPSCs from familial and sporadic AD showed higher levels
of Ab and pTau181 compared with those from controls.
These studies indicated that it is possible to generate
iPSC-derived neurons from elderly patients that capture
basic biochemical changes associated with disease states
yielding potential in vitro systems for compound screening.
Promising recent technical developments also suggest the
feasibility of producing iPSCs with appropriate disease
phenotypes from LCLs [139]. This could be very important
in maximizing the value of ADNI data as LCLs are avail-
able for almost every participant from all study phases
(ADNI-1/GO/2).
The vast majority of AD cases are sporadic with con-
tributions from multiple genetic and environmental fac-
tors. Although individuals with AD share similar
pathologic changes, the patient population is highly het-
erogeneous. The preliminary comparison reported by
Israel et al. showed that only one of the two sporadic
AD iPSC-differentiated neurons shared similar pheno-
types with those from familial AD participants, indicating
that sporadic AD patients may have different degrees of
similarity to familial AD phenotypes. A larger panel of
iPSC lines derived from sporadic AD patients may pro-
vide further information related to disease heterogeneity
and help define potential disease subtypes within sporadic
AD. Recent work from the University of California, San
Diego group suggests the potential of iPSC studies to
identify molecular phenotypic signatures associated with
established AD candidate genes such as SORL1
[sortilin-related receptor, L(DLR class) A repeats contain-
ing] [140].
ADNI has stimulated international efforts to charac-
terize AD phenotypes across a number of technology plat-
forms including imaging, biochemistry, and genetics.
iPSC lines derived from these cohorts, including prodro-
mal dementia participants and cognitively normal at-risk
participants with rich characterizations, will enable link-
ing in vitro molecular profiles (e.g., epigenetic changes)
with other relevant disease phenotypes. In fact, the next
phase of ADNI would be well positioned to collect sam-
ples for iPSC development on a large series of older
adults at risk for MCI and AD with highly detailed pheno-
typic characterization that could help to determine the
relationship between clinical and pathophysiological phe-
notypes and cellular/molecular phenotypes. Recent devel-
opments in three-dimensional culture systems may permit
capture of additional disease features such as neurofibril-
lary tangles [141]. This will provide better in vitro model
systems to understand disease mechanisms that, combined
with improved phenotypic characterization of disease het-
erogeneity, can be expected to advance AD therapeutics
and move the field closer to the goal of precision
medicine.4.4. Return of research results to participants
The topic of return of research results (RORR) to research
participants and/or their physicians has been a source of
considerable interest and controversy across the entire spec-
trum of the research enterprise [142–144], but particularly in
the domains of imaging [145–147] and genetics [148–150].
In brief, as human studies systematically collect
information on participants, participants may request the
information, and arguments may be made for participant
benefit of receiving this information. Discussions of RORR
sometimes differentiate information that is relevant to the
disease in question and the aims of the study (sometimes
called “incidental research findings”) versus information
unrelated to the purpose of the study (sometimes referred
to as “incidental findings”). The discussion also sometimes
differentiates RORR that are aligned with clinical standards
of care (e.g., returning an unexpectedly elevated blood
pressure or the presence of an unexpected mass on an
imaging study) versus returning results that are not yet part
of expected standards of clinical care where the
implications of the results may not yet be well understood
(such as new assays or novel imaging modalities).
There have been active discussions about RORR within
various ADNI committees and within the ADNI Genetics
Core. Institutional review boards (IRBs) at various ADNI
clinical sites have also raised questions with regard to how
both imaging and genetic RORR issues should be handled.
In ADNI, the issue has arisen in two principal areas: amyloid
PET imaging and genomics.4.4.1. RORR for amyloid PET imaging
A large subset of ADNI participants received amyloid
PET scans as part of the ADNI research protocol. In
some of these instances, either the participants themselves
have requested their amyloid PET results or their clinicians
(who are sometimes also the ADNI investigators at that
particular site) have requested the results of the amyloid
PET scans to influence the clinical care of these partici-
pants—particularly among CN participants who are found
to have positive amyloid PET scans. Arguments against
disclosing these data were that they were ordered outside
of the clinical work stream, often in situations (such as
in unaffected individuals) that were outside the scope of
current medical practice, and that they were not all neces-
sarily read in a standardized way by interpreters who had
been trained to render a clinical report. A further argument
against disclosing these results was that a major component
of the scientific value of ADNI is in the correlative ana-
lyses between cognitive testing, biomarker collection,
structural and functional imaging, and longitudinal
outcome. Indeed, it has been demonstrated that simply
learning that one has a neurocognitive diagnosis [151], or
that one is at increased genetic risk for AD dementia
[152], can have a deleterious effect on neurocognitive per-
formance. If the results of amyloid PET scans performed
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the clinical work stream, the choices of clinicians and the
reactions of participants could be altered in ways that could
diminish the scientific validity of the results.
Arguments for RORR to participants and their clinicians
are predominantly focused on the autonomy of participants
and the rights of participants to learn information about
themselves that could influence their health [142,150].
There is also the universal appetite among research
participants of all types for the return of health-related
research information [153]. In just the arena of dementia, a
nationally representative survey of US adults [154], and an
entirely separate survey of adults in the United States and
four European countries [155], showed that nearly 70% of
those queried would take a test to learn more about their
risk of AD, even if no preventative treatment was available.
In a 2012 survey of 260 academic physicians specializing in
dementia care and research, 135 (52%) responded, and of
those, 24% reported that if amyloid scans were FDA
approved and covered by insurance, they planned to use
this technology for screening asymptomatic individuals
[156]. Since that time, published guidelines have recommen-
ded against amyloid scans in CN individuals [157,158], and
US Centers for Medicare and Medicaid Services (CMS)
issued a decision denying payment for clinical use of this
technology [159,160]. Of note, CMS approved coverage
with evidence development for amyloid PET in which
patients meeting appropriate use criteria can receive
coverage if they are enrolled in an approved comparative
effectiveness trial designed to clarify the benefit to clinical
care. In our 2012 survey of ADNI investigators asking
respondents to assume FDA approval of [18F]florbetapir
over half of the 159 respondents indicated that CN study
participants had requested the results of their amyloid
scans and nine respondents (6%) reported that they had
already disclosed amyloid imaging results to these
participants [161].
Within ADNI, there was a considerable range of opinion
regarding the policy that should be adopted for RORR of am-
yloid PET scans, and in 2012, a policy was adopted that rec-
ommended against the RORR for this modality (http://www.
adni-info.org/scientists/doc/10_Green_RORR.pdf). These
issues are likely to be revisited periodically in this rapidly
evolving area.
4.4.2. RORR for biomarkers and genetic variants
In addition to imaging studies, ADNI generates
individual-level data on a variety of serum, plasma, and
CSF biomarkers (see ADNI Biomarker Core report in this
special issue), as well as the genotype and sequencing results
described earlier in this article. In the areas of biomarkers
and genetic variants related to AD, the arguments for and
against disclosure are similar to those made about research
imaging results, that is, respect for participant autonomy
and possible benefit to ongoing and future medical care
versus the possibility that longitudinal measures of impor-tant outcomes could be biased by RORR or by actions taken
in response to RORR. In the area of laboratory tests, there is
another consideration, which is that most of the biomarker
and genetic data are generated in laboratories that are not
CLIA certified. CLIA is the Clinical Laboratory Improve-
ment Amendments certification by CMS that regulates qual-
ity assurance in human clinical laboratory testing in the
United States. The position of CMS, and of most IRBs, is
quite unambiguously that no health-related laboratory re-
sults should be returned to participants unless those results
are generated (or replicated) in a CLIA-certified laboratory
[162,163].
As large-scale studies such as ADNI collect and analyze
genomic information, the societal trends toward RORRs and
individual empowerment are encouraging extensive discus-
sion about whether specific processes should be put in place
to return incidental or secondary genomic findings of medi-
cal importance [150,164]. Similar discussions have been
occurring in the clinical realm as WES and WGS are
increasingly being used in clinical diagnosis [165,166],
sparked in part by the recommendations of the American
College of Medical Genetics and Genomics (ACMG) that
were published in 2013 and updated in 2015 [167,168].
The ACMG recommended that an explicit panel of
mutations in specific genes should be routinely assessed
when sequencing is performed for clinical purposes. The
ACMG recommendations recognized that this area is
evolving and suggested a need for regular reevaluations of
the minimum list, as well as the importance of clear
communication with the patient, but attempted to place the
return of secondary findings in clinical sequencing
squarely within existing traditions of clinical medicine
[169]. These discussions in the clinical arena have prompted
extensive considerations by researchers and IRBs about the
distinctions between the clinical and research domains
[162,163], but consensus recommendations appear to be
evolving toward the position that genomic results of
medical importance and medical actionability should be
shared with research participants and after the death of
participants, with their families, particularly if the consent
forms are clearly written to include this contingency
[150,170].
Large-scale genotyping and sequencing in a dementia
study raises a number of other issues. Many individuals
and families are interested in learning their APOE genotype,
as this is a risk marker for AD that has becomewidely recog-
nized throughout society. APOE genotype is a robust marker
for AD risk but does not meet the criteria for medical impor-
tance and medical actionability that have been described in
the aforementioned referenced discussions of RORR.
Thus, although clinical trials have demonstrated that
APOE genotype can be returned without undue distress
[171–174], this is not typically included in discussions of
possible genomic RORR.
Both imaging and genome-scale testing also raise issues
of reidentifiability. With high-resolution MRI scanning, it
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where they might be identifiable. There have also been
well-publicized accounts in which de-identified genomes
could be linked to specific surnames, and potentially to spe-
cific individuals, through linkage to publically available da-
tabases [175]. In this regard, ADNI genomes are as
vulnerable, or protected, as other genomes that are being
made available to qualified researchers through various
sharing mechanisms such as dbGaP. Although reidentifica-
tion through imaging or genomic information is therefore
possible, it is strictly prohibited by ADNI policies and by
IRBs, and any attempt to do so by investigators would be
in clear violation of these policies.
In summary, the RORR to participants in ADNI has not
been pursued to date because ADNI consent forms do not
promise that incidental findings will be returned and, in
some cases, are explicit in noting that they will not be re-
turned. It remains to be seen if IRB policies toward return
of incidental genomic information will request or require
ADNI sites to revisit this question in the years ahead.4.5. Future plans, related initiatives, and conclusions
ADNI-2 is now about to enter its final year, and plans
are being finalized for the ADNI-3 proposal to continue
and extend this research in important new directions. Tau
PET imaging studies, computer-based cognitive assess-
ments, and other new features will be added this year
and hopefully carried forward into the next phase of
ADNI. From a genetic perspective, these novel phenotypes
will be important topics for future association studies. In
addition to continued banking, dissemination, and assays
on longitudinal genetic biosample data, major plans
include analysis of existing baseline and follow-up visit
data and similar collection and analysis of new participants
to be recruited in the future. Most resources available to the
Genetics Core are for sample collection and processing.
However, analysis of existing data on the association of ge-
netic variation and key clinical/cognitive, imaging, and
biomarker phenotypes is a priority.
Longitudinal blood RNA and epigenetic markings
(including but not limited to methylation) in DNA will
be important and potentially highly informative. As
discussed previously, a longitudinal convergent “multi-
omics” collection and analysis strategy will continue,
along with the challenge of finding resources for com-
plete analysis and dissemination of all biosample results.
Partnerships with the Alzheimer’s Association, other
foundations and donors, and ADNI’s industry partners
via the Foundation for the National Institutes of Health
have made possible the early ADNI-1 GWAS, the recent
WGS on .800 samples, and the RNA expression
profiling using blood samples from most of the same par-
ticipants.
The ADNI Genetics Core hosts an extended working
group that holds conference calls monthly or more oftenas needed. The Genetics Core also sponsors an ad hoc
RNA working group to support collaborative expression
profiling and transcriptome analysis. Furthermore, the Ge-
netics Core has recently established an ADNI systems
biology working group to enhance the potential contribu-
tions of this specialized area for analysis of ADNI data
and for collaboration on analyses that span multiple data
types and cohorts. Thought leaders in systems biology
and network medicine from academia, foundations, and in-
dustry are engaged in determining the key scientific ques-
tions, opportunities, and priorities that these areas of
science can contribute to ADNI.
The ADNI Genetics Core has served as a liaison to rele-
vant consortia, including the Alzheimer’s Disease Genetics
Consortium/Alzheimer’s Disease Sequencing Project,
Religious Order Study/Rush Memory and Aging Project,
AddNeuroMed, World-Wide ADNI, ENIGMA, Multi-
Institutional Research in Alzheimer’s Genetic Epidemi-
ology, IMAS, and HRS investigators, as well as other
cohort studies that could serve as replication samples or
collaborate in other synergistic research activities. Various
inquiries about ADNI genetic data within and outside of
ADNI have been addressed to encourage the individual
and collaborative investigation of ADNI genetic data. Cur-
rent plans also include direct comparisons between ADNI
and the autosomal dominant form of AD seen in the Domi-
nantly Inherited Alzheimer Network consortium. One lim-
itation of ADNI genetic analyses is the absence of large
data sets for replication with the vast array of imaging
and fluid biomarkers available in ADNI. To date, some
studies have used local data sets not publically shared, as
well as some partially publically available data sets. Addi-
tional open data sharing in the future will assist in
providing replication samples for ADNI genetic analyses.
Furthermore, when genetic data become available for the
Australian Imaging, Biomarker & Lifestyle Flagship Study
of Ageing study and other publically available cohorts in
the World-Wide ADNI consortium, there will be tremen-
dously enhanced power to detect associations and replicate
ADNI genetic findings.
As promising leads are discovered using ADNI genetic
and phenotypic data, there is potentially very high scien-
tific and translational value to be gained from follow-up
with functional genomics experiments (as illustrated in
Fig. 4). One particularly promising direction for func-
tional genomics follow-on studies is creation of iPSCs
from blood or fibroblast samples collected from the
ADNI cohort. iPSCs coupled with other clinical and im-
aging information from the same individual would help
to construct “dementia-on-a-chip” models for assessing
candidate diagnostic and therapeutic agents. Although it
is beyond the scope of ADNI to follow-up all promising
leads, the Genetics Core will continue to facilitate and co-
ordinate with partners and the research community to
enable these experiments to be conducted and results
shared expeditiously. Finally, given the complexity of
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analytic strategies closely linked to biological knowledge
need to be adapted and applied to ADNI data. Fortunately,
the computational science community is stepping up to
this challenge with dozens of publications using advanced
strategies to interrogate ADNI data, and the Genetics Core
looks forward to supporting and collaborating with such
efforts to extract biologically significant and clinically
relevant information from the proverbial haystack of in-
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1. Systematic review: Here we provide an update on the
repository of banked genetic materials and quality-
controlled data sets available from the ADNI
cohort; we highlight some of the key studies that
have analyzed these data. PubMed was searched for
(1) “All Fields” containing “Alzheimer’s Disease
Neuroimaging Initiative”; (2) “All Fields” containing
“APOE,” “apolipoprotein,” “gene,” “genetic,” “ge-
netics,” “genome,” “genomic,” or “genomics”; and
(3) “Year” between 2008 and 2014. Results were
integrated with a review of the ADNI Data and
Publications Committee database.
2. Interpretation: Relevant publications were identified
(n 5 313), analyzed, and tabulated, and results are
discussed. Key information is summarized for users
of these data sets. We also discuss implications for
diagnostic and therapeutic precision medicine
including novel drug target identification, clinical
trial design, and enrichment strategies.
3. Future directions: We also discussed conceptual direc-
tions, such as applying concepts from systems biology
to the rich longitudinalmultiomics and phenotypic data
sets in ADNI and prospects for incorporating samples
to support induced pluripotent stem cells in future.References
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